X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bhq880 (4) 4
bone-disease (3) 3
index medicus (3) 3
multiple myeloma (3) 3
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
daratumumab (2) 2
denosumab (2) 2
dickkopf-1 (2) 2
diseases (2) 2
dkk1 (2) 2
elotuzumab (2) 2
hematology (2) 2
humans (2) 2
molecular targeted therapy (2) 2
multiple myeloma - complications (2) 2
multiple myeloma - drug therapy (2) 2
relapse (2) 2
serum concentrations (2) 2
stem-cell transplantation (2) 2
880 (1) 1
ace-011 (1) 1
aged (1) 1
anabolic agents - administration & dosage (1) 1
anabolic agents - adverse effects (1) 1
anabolic agents - pharmacokinetics (1) 1
anabolic agents - therapeutic use (1) 1
anti-hm1.24 mab (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - pharmacokinetics (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
atacicept (1) 1
bevacizumab (1) 1
bhq (1) 1
biological products (1) 1
bone density conservation agents - administration & dosage (1) 1
bone density conservation agents - adverse effects (1) 1
bone density conservation agents - therapeutic use (1) 1
bone disease (1) 1
bone diseases - drug therapy (1) 1
bone diseases - etiology (1) 1
bone remodeling (1) 1
bone resorption - drug therapy (1) 1
bone resorption - prevention & control (1) 1
bones (1) 1
bortezomib (1) 1
cancer (1) 1
care and treatment (1) 1
cell-adhesion (1) 1
chemotherapy (1) 1
clinical trials as topic (1) 1
cnto 328 (1) 1
combination (1) 1
density (1) 1
dexamethasone (1) 1
diphosphonates - administration & dosage (1) 1
diphosphonates - adverse effects (1) 1
diphosphonates - therapeutic use (1) 1
double-blind (1) 1
drug therapy (1) 1
drug therapy, combination (1) 1
endocrinology & metabolism (1) 1
female (1) 1
fractures, spontaneous - etiology (1) 1
growth (1) 1
hematology, oncology and palliative medicine (1) 1
hla class-i (1) 1
huluc63 (1) 1
human cd38 (1) 1
hypertension - chemically induced (1) 1
imidazoles - administration & dosage (1) 1
imidazoles - adverse effects (1) 1
imidazoles - therapeutic use (1) 1
immunoglobulin g (1) 1
in-vitro (1) 1
intercellular signaling peptides and proteins - immunology (1) 1
lenalidomide (1) 1
lorvotuzumab (1) 1
low-dose dexamethasone (1) 1
male (1) 1
mapatumumab (1) 1
maximum tolerated dose (1) 1
medical research (1) 1
medicine, experimental (1) 1
middle aged (1) 1
milatuzumab (1) 1
monoclonal antibodies (1) 1
multiple myeloma - mortality (1) 1
multiple myeloma - pathology (1) 1
neoplasm proteins - antagonists & inhibitors (1) 1
open-label (1) 1
osteoblasts (1) 1
osteolysis - blood (1) 1
osteolysis - drug therapy (1) 1
osteolysis - etiology (1) 1
pembrolizumab (1) 1
phase i (1) 1
phase-i trial (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Bone, ISSN 8756-3282, 08/2018, Volume 113, pp. 114 - 117
Recent studies have shown that Dickkopf-related protein (DKK1) and sclerostin decrease when a complete response (CR) is obtained after chemotherapy in myeloma... 
Sclerostin | Bone remodeling | DKK1 | Multiple myeloma | BONE-DISEASE | DEXAMETHASONE | DICKKOPF-1 | THALIDOMIDE | BORTEZOMIB | COMBINATION | SERUM CONCENTRATIONS | ENDOCRINOLOGY & METABOLISM | RECEPTOR ACTIVATOR | BHQ880 | STEM-CELL TRANSPLANTATION | Relapse | Chemotherapy | Diseases | Cancer
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 366 - 375
Dickkopf‐1 ( DKK 1), expressed by myeloma cells, suppresses osteoblast function and plays a key role in bone disease in multiple myeloma. BHQ 880, a human... 
880 | multiple myeloma | BHQ | Phase I | skeletal‐related event | BHQ880 | Multiple myeloma | Skeletal-related event | BONE-DISEASE | DICKKOPF-1 | skeletal-related event | DKK1 | IN-VITRO | SERUM CONCENTRATIONS | OSTEOBLASTS | GROWTH | DOUBLE-BLIND | RECEPTOR-RELATED PROTEIN-5 | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Imidazoles - administration & dosage | Antibodies, Monoclonal - therapeutic use | Male | Neoplasm Proteins - antagonists & inhibitors | Osteolysis - etiology | Molecular Targeted Therapy | Osteolysis - drug therapy | Multiple Myeloma - drug therapy | Hypertension - chemically induced | Diphosphonates - therapeutic use | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Diphosphonates - adverse effects | Anabolic Agents - therapeutic use | Bone Density Conservation Agents - adverse effects | Multiple Myeloma - complications | Imidazoles - adverse effects | Anabolic Agents - adverse effects | Bone Resorption - drug therapy | Antibodies, Monoclonal - pharmacokinetics | Bone Density Conservation Agents - therapeutic use | Fractures, Spontaneous - etiology | Diphosphonates - administration & dosage | Spinal Cord Compression - etiology | Bone Density Conservation Agents - administration & dosage | Bone Resorption - prevention & control | Maximum Tolerated Dose | Osteolysis - blood | Anabolic Agents - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Anabolic Agents - pharmacokinetics | Intercellular Signaling Peptides and Proteins - immunology | Medical research | Care and treatment | Relapse | Immunoglobulin G | Medicine, Experimental | Bones | Density | Diseases | Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.